Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 2011. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding their interests in the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary shares by nine individuals on September 9, 2011, at a price of 1315 pence per share through the Company's Share Reward Plan. The transactions involved both personal contributions (partnership element) and company contributions (matching element). Specific acquisitions included:
- Mr A P Witty, Mr S Dingemans, Mr S M Bicknell, Mr E J Gray, Mr D S Redfern, Ms C Thomas, and Mrs V A Whyte each acquired 9 shares via personal contribution and 9 shares via company matching.
- Mr P C Thomson acquired 6 shares via personal contribution and 6 shares via company matching.
- Dr P J T Vallance acquired 10 shares via personal contribution and 10 shares via company matching.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the share transactions described above in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the share price of 1315 pence per Ordinary share on September 9, 2011.
- Confirm the specific number of shares acquired by each named director under the partnership and matching elements of the Share Reward Plan.
- Note that this filing does not contain financial results; investors should refer to Form 20-F or quarterly earnings releases for financial metrics.